ArticleGeburtshilfe und Frauenheilkunde2020
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
Article in Geburtshilfe und Frauenheilkunde, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer.NPJ breast cancer · 2024Article
- Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer - an Analysis of a Large University Breast Cancer Centre.Geburtshilfe und Frauenheilkunde · 2023Article
- Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer.Geburtshilfe und Frauenheilkunde · 2023Article
- Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.Geburtshilfe und Frauenheilkunde · 2022Article
- Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis.Geburtshilfe und Frauenheilkunde · 2022Article
- Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement.Cancers · 2021Review
- Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and Biomarkers.Geburtshilfe und Frauenheilkunde · 2021Article
- Update Breast Cancer 2021 Part 1 - Prevention and Early Stages.Geburtshilfe und Frauenheilkunde · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.